GB9316895D0
(en)
*
|
1993-08-13 |
1993-09-29 |
Guy S And St Thomas Hospitals |
Hepatoselective insulin analogues
|
US6342225B1
(en)
|
1993-08-13 |
2002-01-29 |
Deutshces Wollforschungsinstitut |
Pharmaceutical active conjugates
|
US6869930B1
(en)
|
1993-09-17 |
2005-03-22 |
Novo Nordisk A/S |
Acylated insulin
|
DE4437604A1
(de)
*
|
1994-10-21 |
1996-04-25 |
Basf Ag |
Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
|
US5646242A
(en)
*
|
1994-11-17 |
1997-07-08 |
Eli Lilly And Company |
Selective acylation of epsilon-amino groups
|
US5693609A
(en)
*
|
1994-11-17 |
1997-12-02 |
Eli Lilly And Company |
Acylated insulin analogs
|
EP0871665B1
(en)
*
|
1995-03-17 |
2003-07-23 |
Novo Nordisk A/S |
Insulin derivatives
|
US6251856B1
(en)
|
1995-03-17 |
2001-06-26 |
Novo Nordisk A/S |
Insulin derivatives
|
US20010041786A1
(en)
*
|
1995-06-07 |
2001-11-15 |
Mark L. Brader |
Stabilized acylated insulin formulations
|
GB9513967D0
(en)
*
|
1995-07-08 |
1995-09-06 |
Univ Leicester |
Insulin
|
US6451970B1
(en)
*
|
1996-02-21 |
2002-09-17 |
Novo Nordisk A/S |
Peptide derivatives
|
ATE208208T1
(de)
*
|
1996-06-20 |
2001-11-15 |
Novo Nordisk As |
Halogenid-enthaltende insulinzubereitungen
|
US5905140A
(en)
*
|
1996-07-11 |
1999-05-18 |
Novo Nordisk A/S, Novo Alle |
Selective acylation method
|
ES2230607T3
(es)
*
|
1996-07-11 |
2005-05-01 |
Novo Nordisk A/S |
Metodo selectivo de acilacion.
|
US20020025933A1
(en)
*
|
1996-08-30 |
2002-02-28 |
Knudsen Liselotte Bjerre |
GLP-2 derivatives
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US5898067A
(en)
*
|
1997-02-07 |
1999-04-27 |
Novo Nordisk A/S |
Crystallization of proteins
|
US6043214A
(en)
*
|
1997-03-20 |
2000-03-28 |
Novo Nordisk A/S |
Method for producing powder formulation comprising an insulin
|
KR20000076419A
(ko)
*
|
1997-03-20 |
2000-12-26 |
한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 |
폐 투여용 무아연 인슐린 결정 조성물
|
US6310038B1
(en)
*
|
1997-03-20 |
2001-10-30 |
Novo Nordisk A/S |
Pulmonary insulin crystals
|
US6451762B1
(en)
|
1997-10-24 |
2002-09-17 |
Novo Nordisk A/S |
Aggregates of human insulin derivatives
|
EP0911035A3
(en)
*
|
1997-10-24 |
2002-08-21 |
Eli Lilly And Company |
Insoluble insulin compositions
|
KR20010024556A
(ko)
*
|
1997-10-24 |
2001-03-26 |
피터 지. 스트링거 |
불용성 인슐린 조성물
|
US6444641B1
(en)
|
1997-10-24 |
2002-09-03 |
Eli Lilly Company |
Fatty acid-acylated insulin analogs
|
ZA989744B
(en)
*
|
1997-10-31 |
2000-04-26 |
Lilly Co Eli |
Method for administering acylated insulin.
|
EP1396272A1
(en)
*
|
1997-12-23 |
2004-03-10 |
Eli Lilly & Company |
Insoluble Insulin Compositions for Controlling Blood Glucose
|
CO4970787A1
(es)
*
|
1997-12-23 |
2000-11-07 |
Lilly Co Eli |
Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
|
EP1044016B1
(en)
*
|
1998-01-09 |
2005-03-16 |
Novo Nordisk A/S |
Stabilised insulin compositions
|
JP2002504527A
(ja)
*
|
1998-02-27 |
2002-02-12 |
ノボ ノルディスク アクティーゼルスカブ |
部分的に組織化したミセル様凝集物を形成する25%を越えるヘリックス成分を有するglp−2誘導体
|
DE19825447A1
(de)
*
|
1998-06-06 |
1999-12-09 |
Hoechst Marion Roussel De Gmbh |
Neue Insulinanaloga mit erhöhter Zinkbildung
|
JP2002518408A
(ja)
*
|
1998-06-12 |
2002-06-25 |
キングス・カレツジ・ロンドン |
インスリン類似体
|
US7169889B1
(en)
*
|
1999-06-19 |
2007-01-30 |
Biocon Limited |
Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
|
ATE328605T1
(de)
|
2000-03-24 |
2006-06-15 |
Genentech Inc |
Verwendung von insulin zur behandlung von knorpelkrankheiten
|
AU2001254621A1
(en)
*
|
2000-05-05 |
2001-11-20 |
K.U. Leuven R And D |
Critical illness neuropathy
|
US7316999B2
(en)
|
2000-06-02 |
2008-01-08 |
Novo Nordisk A/S |
Glucose dependent release of insulin from glucose sensing insulin derivatives
|
CA2415425A1
(en)
*
|
2000-07-10 |
2002-01-17 |
Btg International Limited |
Insulin derivatives and synthesis thereof
|
US20030054015A1
(en)
*
|
2000-12-25 |
2003-03-20 |
Shinichiro Haze |
Sympathetic-activating perfume composition
|
US6867183B2
(en)
*
|
2001-02-15 |
2005-03-15 |
Nobex Corporation |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US7060675B2
(en)
*
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
US6653492B2
(en)
|
2001-05-02 |
2003-11-25 |
Novo Nordick A/S |
Preparation of bile acids
|
EP1385867B1
(en)
*
|
2001-05-02 |
2006-08-30 |
Novo Nordisk A/S |
Preparation of bile acids
|
US6828297B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6835802B2
(en)
*
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
US6858580B2
(en)
*
|
2001-06-04 |
2005-02-22 |
Nobex Corporation |
Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6713452B2
(en)
*
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7713932B2
(en)
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
US6828305B2
(en)
*
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7595172B2
(en)
|
2001-07-24 |
2009-09-29 |
Novo Nordisk A/S |
Method for making acylated polypeptides
|
WO2003020201A2
(en)
|
2001-08-28 |
2003-03-13 |
Eli Lilly And Company |
Pre-mixes of glp-1 and basal insulin
|
US7176278B2
(en)
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
US6913903B2
(en)
*
|
2001-09-07 |
2005-07-05 |
Nobex Corporation |
Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7312192B2
(en)
*
|
2001-09-07 |
2007-12-25 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
WO2003022996A2
(en)
|
2001-09-07 |
2003-03-20 |
Nobex Corporation |
Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7196059B2
(en)
*
|
2001-09-07 |
2007-03-27 |
Biocon Limited |
Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
|
US7166571B2
(en)
*
|
2001-09-07 |
2007-01-23 |
Biocon Limited |
Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
JP4563675B2
(ja)
|
2001-10-12 |
2010-10-13 |
ハイ・ポイント・ファーマスーティカルズ、エルエルシー |
置換ピペリジン類、およびヒスタミンh3受容体関連疾患の治療のためのその使用
|
JP2005508360A
(ja)
|
2001-10-19 |
2005-03-31 |
イーライ・リリー・アンド・カンパニー |
Glp−1およびインスリンの二相混合物
|
WO2003044210A2
(en)
|
2001-11-19 |
2003-05-30 |
Novo Nordisk A/S |
Process for preparing insulin compounds
|
GB0206792D0
(en)
|
2002-03-22 |
2002-05-01 |
Leuven K U Res & Dev |
Normoglycemia
|
EP1506230B1
(en)
*
|
2002-05-07 |
2011-01-19 |
Novo Nordisk A/S |
Soluble formulations comprising monomeric insulin and acylated insulin
|
US20040038864A1
(en)
*
|
2002-06-27 |
2004-02-26 |
Per Balschmidt |
Use of dimethyl sulfone as isotonicity agent
|
EP1546090B1
(en)
*
|
2002-09-25 |
2009-06-24 |
Novo Nordisk A/S |
Method for producing acylated peptides
|
US7273921B2
(en)
|
2002-09-25 |
2007-09-25 |
Novo Nordisk A/S |
Method for producing acylated peptides
|
US7411039B2
(en)
|
2002-10-14 |
2008-08-12 |
Novo Nordisk A/S |
GLP-2 compounds, formulations, and uses thereof
|
US20040138099A1
(en)
*
|
2002-11-29 |
2004-07-15 |
Draeger Eberhard Kurt |
Insulin administration regimens for the treatment of subjects with diabetes
|
WO2004085472A1
(en)
*
|
2003-03-27 |
2004-10-07 |
Novo Nordisk A/S |
Method for making human insulin precursors and human insulin
|
ATE482747T1
(de)
|
2003-04-11 |
2010-10-15 |
High Point Pharmaceuticals Llc |
Neue amide derivate und deren pharmazeutische verwendungen
|
WO2004096266A1
(en)
*
|
2003-05-02 |
2004-11-11 |
Novo Nordisk A/S |
Improved physical stability of insulin formulations
|
DE602004032237D1
(de)
|
2003-06-27 |
2011-05-26 |
Novo Nordisk As |
Behälter für medizinische flüssigkeiten mit hoher wasserdampfsperre
|
PL2275439T3
(pl)
|
2003-08-05 |
2014-09-30 |
Novo Nordisk As |
Nowe pochodne insuliny
|
EP2107069B1
(en)
*
|
2003-08-05 |
2013-01-16 |
Novo Nordisk A/S |
Novel insulin derivatives
|
WO2005047508A1
(en)
|
2003-11-14 |
2005-05-26 |
Novo Nordisk A/S |
Processes for making acylated insulin
|
RU2421238C2
(ru)
|
2003-11-20 |
2011-06-20 |
Ново Нордиск А/С |
Пептидная композиция, содержащая пропиленгликоль, являющаяся оптимальной для изготовления и применения в инъекционных устройствах
|
EP1692168B1
(en)
|
2003-12-03 |
2011-07-20 |
Novo Nordisk A/S |
Single-chain insulin
|
JP2007515235A
(ja)
|
2003-12-22 |
2007-06-14 |
ノボ・ノルデイスク・エー/エス |
医薬液を保存するための、透明で、可撓性且つ不浸透性のプラスチック製容器
|
CN1909930B
(zh)
|
2004-01-21 |
2015-12-16 |
诺和诺德医疗保健公司 |
转谷氨酰胺酶介导的肽的接合
|
ES2398838T3
(es)
*
|
2004-03-12 |
2013-03-22 |
Biodel, Inc. |
Composiciones de suministro de fármacos de acción rápida
|
WO2006008238A1
(en)
*
|
2004-07-16 |
2006-01-26 |
Novo Nordisk A/S |
Method for selective acylation
|
US7875700B2
(en)
|
2004-07-19 |
2011-01-25 |
Biocon Limited |
Cation complexes of insulin compound conjugates, formulation and uses thereof
|
US7833513B2
(en)
|
2004-12-03 |
2010-11-16 |
Rhode Island Hospital |
Treatment of Alzheimer's Disease
|
ES2490243T3
(es)
|
2005-02-02 |
2014-09-03 |
Novo Nordisk A/S |
Derivados de insulina
|
EP1846446B1
(en)
|
2005-02-02 |
2013-06-26 |
Novo Nordisk A/S |
Insulin derivatives
|
CN101180081B
(zh)
|
2005-05-25 |
2015-08-26 |
诺沃-诺迪斯克有限公司 |
稳定的多肽制剂
|
US20090060861A1
(en)
*
|
2005-05-25 |
2009-03-05 |
Novo Nordisk A/S |
Stabilized Polypeptide Formulations
|
EP1888104A2
(en)
*
|
2005-05-26 |
2008-02-20 |
Novo Nordisk A/S |
Acylated insulin with high purity
|
EP2233470B1
(en)
|
2005-07-04 |
2011-12-07 |
High Point Pharmaceuticals, LLC |
Histamine H3 receptor antagonists
|
EP1910317B1
(en)
|
2005-07-20 |
2013-07-03 |
Eli Lilly And Company |
1-amino linked compounds
|
WO2007020256A1
(en)
|
2005-08-16 |
2007-02-22 |
Novo Nordisk A/S |
Method for making mature insulin polypeptides
|
US7741281B2
(en)
*
|
2005-11-03 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2007123581A1
(en)
|
2005-11-17 |
2007-11-01 |
Eli Lilly And Company |
Glucagon receptor antagonists, preparation and therapeutic uses
|
EP1969004B1
(en)
|
2005-12-28 |
2011-08-10 |
Novo Nordisk A/S |
Compositions comprising an acylated insulin and zinc and method of making the said compositions
|
EP1984009B1
(en)
|
2006-01-18 |
2012-10-24 |
Qps, Llc |
Pharmaceutical compositions with enhanced stability
|
EP2256129B1
(en)
|
2006-02-27 |
2012-05-09 |
Novo Nordisk A/S |
Insulin derivatives
|
US20090069215A1
(en)
*
|
2006-03-13 |
2009-03-12 |
Novo Nordisk A/S |
Acylated Single Chain Insulin
|
EP1996224B1
(en)
|
2006-03-15 |
2012-11-07 |
Novo Nordisk A/S |
Mixtures of amylin and insulin
|
EP1999120B1
(en)
|
2006-03-28 |
2012-06-27 |
High Point Pharmaceuticals, LLC |
Benzothiazoles having histamine h3 receptor activity
|
ATE543798T1
(de)
|
2006-04-24 |
2012-02-15 |
Lilly Co Eli |
Cyclohexyl-substituierte pyrrolidinone als hemmer von 11-beta-hydroxysteroiddehydrogenase 1
|
EP2024390B1
(en)
|
2006-05-09 |
2015-08-19 |
Novo Nordisk A/S |
Insulin derivative
|
CN101437849B
(zh)
*
|
2006-05-09 |
2015-09-30 |
诺沃-诺迪斯克有限公司 |
胰岛素衍生物
|
BRPI0712041A2
(pt)
|
2006-05-09 |
2011-12-27 |
Novo Nordisk As |
derivado de insulina
|
US7714025B2
(en)
*
|
2006-05-10 |
2010-05-11 |
Arizona Biomedical Research Commission |
Modified chalcone compounds as antimitotic agents
|
ES2375872T3
(es)
|
2006-05-29 |
2012-03-07 |
High Point Pharmaceuticals, Llc |
3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperacin-1-il)-piridacina, sus sales y solvatos, y su uso como antagonista del receptor h3 de la histamina.
|
MX2009000434A
(es)
|
2006-07-11 |
2009-01-29 |
Qps Llc |
Composiciones farmaceuticas para la distribucion de liberacion sostenida de peptidos.
|
JP5550338B2
(ja)
|
2006-07-31 |
2014-07-16 |
ノボ・ノルデイスク・エー/エス |
ペグ化持続型インスリン
|
ES2601839T3
(es)
|
2006-09-22 |
2017-02-16 |
Novo Nordisk A/S |
Análogos de insulina resistentes a proteasas
|
EP2069502B1
(en)
|
2006-09-27 |
2014-02-26 |
Novo Nordisk A/S |
Method for making maturated insulin polypeptides
|
WO2008049711A1
(en)
*
|
2006-10-27 |
2008-05-02 |
Novo Nordisk A/S |
Peptide extended insulins
|
ES2563038T3
(es)
|
2007-04-30 |
2016-03-10 |
Novo Nordisk A/S |
Método para secar una composición proteica, una composición proteica seca y una composición farmacéutica que comprende la proteína seca
|
EP2514407A1
(en)
|
2007-06-01 |
2012-10-24 |
Novo Nordisk A/S |
Stable non-aqueous pharmaceutical compositions
|
EP2514406A1
(en)
|
2007-06-01 |
2012-10-24 |
Novo Nordisk A/S |
Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
|
ES2744384T3
(es)
|
2007-06-13 |
2020-02-24 |
Novo Nordisk As |
Formulación farmacéutica que comprende un derivado de insulina
|
ES2558930T3
(es)
|
2007-08-13 |
2016-02-09 |
Novo Nordisk A/S |
Análogos de la insulina de acción rápida
|
MX2010003979A
(es)
*
|
2007-10-16 |
2010-06-02 |
Biocon Ltd |
Composicion farmaceutica oralmente administrable y proceso para su preparacion.
|
EP2058330A1
(en)
*
|
2007-11-08 |
2009-05-13 |
Novo Nordisk A/S |
Insulin derivative
|
WO2009060071A1
(en)
*
|
2007-11-08 |
2009-05-14 |
Novo Nordisk A/S |
Insulin derivative
|
EP2209800B1
(en)
|
2007-11-16 |
2013-07-24 |
Novo Nordisk A/S |
Stable pharmaceutical compositions comprising liraglutide and degludec
|
WO2009089181A1
(en)
*
|
2008-01-04 |
2009-07-16 |
Blodel, Inc. |
Insulin formulations for insulin release as a function of tissue glucose levels
|
US9260502B2
(en)
|
2008-03-14 |
2016-02-16 |
Novo Nordisk A/S |
Protease-stabilized insulin analogues
|
HUE032287T2
(en)
|
2008-03-18 |
2017-09-28 |
Novo Nordisk As |
Protease-stabilized, acylated insulin analogues
|
TWI451876B
(zh)
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
US9090705B2
(en)
|
2008-08-07 |
2015-07-28 |
Biocon Limited |
Process for preparation of insulin compounds
|
RU2540922C2
(ru)
|
2008-10-30 |
2015-02-10 |
Ново Нордиск А/С |
Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день
|
JP2012509879A
(ja)
|
2008-11-21 |
2012-04-26 |
ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー |
アダマンチルベンズアミド化合物
|
PE20120583A1
(es)
|
2009-01-28 |
2012-05-19 |
Smartcells Inc |
Sistemas basados en conjugados para entrega farmacologica controlada
|
EP2391217A4
(en)
|
2009-01-28 |
2015-05-20 |
Smartcells Inc |
SYNTHETIC CONJUGATES AND USES THEREOF
|
US9060927B2
(en)
*
|
2009-03-03 |
2015-06-23 |
Biodel Inc. |
Insulin formulations for rapid uptake
|
JP2012520879A
(ja)
|
2009-03-20 |
2012-09-10 |
スマートセルズ・インコーポレイテツド |
末端官能基化コンジュゲートおよびその用途
|
EP2437786B1
(en)
|
2009-06-01 |
2016-05-18 |
Yeda Research and Development Co. Ltd. |
Prodrugs containing albumin binding probe
|
BR112012012945A2
(pt)
|
2009-11-25 |
2020-12-29 |
Arisgen Sa |
Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo
|
EP2359843A1
(en)
|
2010-01-21 |
2011-08-24 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
AR081066A1
(es)
*
|
2010-04-02 |
2012-06-06 |
Hanmi Holdings Co Ltd |
Conjugado de insulina donde se usa un fragmento de inmunoglobulina
|
US9981017B2
(en)
|
2010-04-02 |
2018-05-29 |
Hanmi Science Co., Ltd. |
Insulin conjugate using an immunoglobulin fragment
|
UY33326A
(es)
|
2010-04-14 |
2011-12-01 |
Sanofi Aventis |
Conjugados de insulina-sirna
|
MX2012012943A
(es)
*
|
2010-05-10 |
2012-11-29 |
Novo Nordisk As |
Proceso para preparacion de complejos de insulina-cinc.
|
WO2012049307A2
(en)
*
|
2010-10-15 |
2012-04-19 |
Novo Nordisk A/S |
Novel n-terminally modified insulin derivatives
|
JP6049625B2
(ja)
|
2010-10-27 |
2016-12-21 |
ノヴォ ノルディスク アー/エス |
様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
|
CN103269723B
(zh)
|
2010-12-22 |
2017-04-05 |
百深有限责任公司 |
用于偶联水溶性脂肪酸衍生物与蛋白质的材料和方法
|
AR085086A1
(es)
|
2011-01-20 |
2013-09-11 |
Zealand Pharma As |
Uso de analogos de glucagon acilados
|
EP2670368A4
(en)
|
2011-02-03 |
2015-04-15 |
Pharmedica Ltd |
NEW ORAL DISSOLUTION FILMS FOR INSULIN DELIVERY FOR THE TREATMENT OF DIABETES
|
US9480751B2
(en)
|
2011-04-11 |
2016-11-01 |
Yeda Research And Development Co. Ltd. |
Albumin binding probes and drug conjugates thereof
|
EP2548570A1
(en)
|
2011-07-19 |
2013-01-23 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
CN102504022A
(zh)
*
|
2011-11-30 |
2012-06-20 |
苏州元基生物技术有限公司 |
含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法
|
IN2014MN00933A
(es)
*
|
2011-12-15 |
2015-05-01 |
Shanghai Hengrui Pharm Co Ltd |
|
CN104364260B
(zh)
|
2012-04-11 |
2017-02-22 |
诺和诺德股份有限公司 |
胰岛素制剂
|
JP6262206B2
(ja)
|
2012-05-01 |
2018-01-17 |
ノヴォ ノルディスク アー/エス |
医薬組成物
|
EP2925345B1
(en)
|
2012-12-03 |
2018-09-05 |
Merck Sharp & Dohme Corp. |
Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
|
EP2991672A1
(en)
|
2013-04-30 |
2016-03-09 |
Novo Nordisk A/S |
Novel administration regime
|
AU2014318579A1
(en)
|
2013-09-13 |
2016-04-14 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
MX366636B
(es)
|
2013-10-07 |
2019-07-17 |
Novo Nordisk As |
Nuevo derivado de un análogo de insulina.
|
US10039809B2
(en)
|
2013-12-18 |
2018-08-07 |
The California Institute For Biomedical Research |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
AR099569A1
(es)
|
2014-02-28 |
2016-08-03 |
Novo Nordisk As |
Derivados de insulina y los usos médicos de estos
|
US9656017B2
(en)
|
2014-06-20 |
2017-05-23 |
Howard E. Greene |
Infusion delivery devices and methods
|
CN107921098A
(zh)
|
2015-06-17 |
2018-04-17 |
加州生物医学研究所 |
修饰的治疗剂及其组合物
|
US11352406B2
(en)
|
2015-08-25 |
2022-06-07 |
Novo Nordisk A/S |
Insulin derivatives and the medical uses hereof
|
WO2018024186A1
(zh)
*
|
2016-08-02 |
2018-02-08 |
江苏恒瑞医药股份有限公司 |
一种人胰岛素或其类似物的酰化衍生物
|
EP3329930A1
(en)
|
2016-12-05 |
2018-06-06 |
Nuritas Limited |
Pharmaceuctical compositions
|
AU2017373651B2
(en)
|
2016-12-05 |
2022-03-10 |
Nuritas Limited |
Compositions comprising peptide wkdeagkplvk
|
TWI700092B
(zh)
|
2016-12-16 |
2020-08-01 |
丹麥商諾佛.儂迪克股份有限公司 |
含胰島素醫藥組成物
|
CN111050750A
(zh)
|
2017-08-24 |
2020-04-21 |
诺沃挪第克公司 |
Glp-1组合物及其用途
|
WO2019066603A1
(ko)
*
|
2017-09-29 |
2019-04-04 |
한미약품 주식회사 |
효력이 향상된 지속성 단백질 결합체
|
EP3727424A4
(en)
|
2017-12-18 |
2021-10-27 |
Merck Sharp & Dohme Corp. |
CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
|
EP3740212A4
(en)
|
2017-12-18 |
2021-10-27 |
Merck Sharp & Dohme Corp. |
CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
|
BR112020015238A2
(pt)
|
2018-02-09 |
2020-12-29 |
Jiangsu Hengrui Medicine Co., Ltd. |
Gene precursor otimizado por códon e gene de peptídeo sinal de análogo de insulina humana
|
CN111601819A
(zh)
|
2018-05-24 |
2020-08-28 |
江苏恒瑞医药股份有限公司 |
一种重组人胰岛素或其类似物的前体的制备方法
|
US10335464B1
(en)
|
2018-06-26 |
2019-07-02 |
Novo Nordisk A/S |
Device for titrating basal insulin
|
KR20200017078A
(ko)
|
2018-08-08 |
2020-02-18 |
주식회사 대웅제약 |
지속형 인슐린 아날로그 및 그 복합체
|
MX2021006972A
(es)
|
2018-12-11 |
2021-08-16 |
Sanofi Sa |
Conjugados de insulina.
|
KR20200080748A
(ko)
|
2018-12-27 |
2020-07-07 |
주식회사 폴루스 |
음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
|
KR20200080747A
(ko)
|
2018-12-27 |
2020-07-07 |
주식회사 폴루스 |
인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
|
CN111909255A
(zh)
*
|
2019-05-10 |
2020-11-10 |
宁波鲲鹏生物科技有限公司 |
胰岛素衍生物及其制备方法
|
TW202120536A
(zh)
|
2019-07-31 |
2021-06-01 |
美商美國禮來大藥廠 |
鬆弛素(relaxin)類似物及其使用方法
|
JP6995284B2
(ja)
|
2019-12-11 |
2022-01-14 |
ノヴォ ノルディスク アー/エス |
新規インスリン類似体およびそれらの使用
|
BR112022013042A2
(pt)
|
2019-12-30 |
2022-10-18 |
Gan & Lee Pharmaceuticals Co Ltd |
Composto da fórmula b, formulação farmacêutica, composição farmacêutica, método para tratar ou prevenir hiperglicemia, diabetes e/ou obesidade
|
JP2023510206A
(ja)
|
2019-12-30 |
2023-03-13 |
甘李薬業股▲フン▼有限公司 |
インスリン誘導体
|
EP4106727A1
(en)
|
2020-02-18 |
2022-12-28 |
Novo Nordisk A/S |
Pharmaceutical formulations
|
JP2023520049A
(ja)
|
2020-03-31 |
2023-05-15 |
プロトマー・テクノロジーズ・インコーポレイテッド |
隣接ジオールに対する選択的応答性のためのコンジュゲート
|
PE20231948A1
(es)
|
2020-11-19 |
2023-12-05 |
Protomer Tech Inc |
Compuestos aromaticos que contienen boro y analogos de insulina
|
EP4180060A1
(en)
|
2021-11-15 |
2023-05-17 |
Adocia |
Solid compositions comprising a peptide or a protein and an acylated amino acid
|
EP4299057A1
(en)
|
2022-06-30 |
2024-01-03 |
Adocia |
Solid compositions comprising a peptide or a protein and an acylated amino acid
|
WO2023084118A1
(en)
|
2021-11-15 |
2023-05-19 |
Adocia |
Solid compositions comprising a peptide or a protein and an acylated amino acid
|
EP4299071A1
(en)
|
2022-07-01 |
2024-01-03 |
Adocia |
Compositions comprising a peptide or a protein and an acylated amino acid
|
WO2024051787A1
(zh)
*
|
2022-09-09 |
2024-03-14 |
北京惠之衡生物科技有限公司 |
一种长效酰化胰岛素衍生物及其应用
|